Once-daily oral daclatasvir plus sofosbuvir was associated with high rates of sustained virologic response among patients infected with HCV genotype 1, 2, or 3, including patients with no response to prior therapy with telaprevir or boceprevir. (Funded by Bristol-Myers Squibb and Pharmasset (Gilead); A1444040 ClinicalTrials.gov number, NCT01359644.).
In a phase 2a study, the all-oral, interferon-free, and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 was well tolerated and achieved high rates of SVR12 in patients with HCV genotype 1 infection. Further studies of this regimen are warranted. ClinicalTrials.gov, number NCT01455090.
Neurotrophins and their receptors (TRKs) play key roles in the development of the nervous system and the maintenance of the neural network. Accumulating evidence points to their role in malignant transformations, chemotaxis, metastasis, and survival signaling and may contribute to the pathogenesis of a variety of tumors of both neural and non-neural origin. By screening the GNF kinase collection, a series of novel oxindole inhibitors of TRKs were identified. Optimization led to the identification of GNF-5837 (22), a potent, selective, and orally bioavailable pan-TRK inhibitor that inhibited tumor growth in a mouse xenograft model derived from RIE cells expressing both TRKA and NGF. The properties of 22 make it a good tool for the elucidation of TRK biology in cancer and other nononcology indications.
A series of 1-acyl-1H-[1,2,4]triazole-3,5-diamine analogues were synthesized as cyclin-dependent kinase (CDK) inhibitors. These compounds showed potent and selective CDK1 and CDK2 inhibitory activities and inhibited in vitro cellular proliferation in various human tumor cells. Representative compound 3b demonstrated in vivo efficacy in a human melanoma A375 xenograft model in nude mice.
A new iterative divergent/convergent solid-phase synthesis of precisely defined oligomers is described. The starting monomer is affixed to the solid support so that both ends are free for growth. The polymer-supported n-mer bearing alpha,omega-terminal iodides is divided into two portions. The smaller portion is converted to the polymer-supported (n + 2)-mer by coupling an alpha,omega-dialkyne to the two iodide ends. The larger portion is liberated from the polymer support and then coupled with the polymer-supported portion to form a polymer-supported (3n + 2)-mer with new alpha,omega-terminal iodide end groups. The process is then repeated. The solid-supported material thereby grows in two directions, unlike the common approach of unidirectional growth. This polymer-supported strategy serves as a pseudo high dilution system so that unwanted polymerization does not ensue. Therefore, after each iteration, the oligomer length is more than tripled, making this a rapid growth methodology for precise oligomer syntheses. The methodology is demonstrated by the synthesis of a 17-mer oligo(1,4-phenylene ethynylene) of approximately 120 Å length in seven steps with an overall 20% yield. This solid-supported divergent/convergent tripling protocol is also used for the synthesis of an [AB] alternating block 23-mer containing oligo(1,4-phenylene ethynylene)s and oligo(2,5-thiophene ethynylene)s in an overall 21% yield. The length of the 23-mer is approximately 160 Å.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.